Chengdu Easton Biopharmaceuticals Hits Day High with 8.49% Surge

Chengdu Easton Biopharmaceuticals Co., Ltd. has experienced a significant uptick in its stock performance, gaining 8.49% on July 10, 2026. The stock reached an intraday high of CNY 58.16, marking a notable achievement in its trading activity. This performance stands in contrast to the China Shanghai Composite, which declined by 1.0% on the same day. Over the past year, Chengdu Easton has generated impressive returns of 79.71%, significantly outperforming the broader market. The company has also shown resilience with a year-to-date performance of -9.23%, while the Shanghai Composite has seen a slight gain of 0.69%. Financially, Chengdu Easton boasts a market capitalization of CNY 8,057 million and a price-to-earnings ratio of 34.00. The company has maintained a solid return on equity of 7.99% and a price-to-book ratio of 2.70. Additionally, its operating cash flow reached a high of CNY 335.41 million, and raw material costs have decreased by 1.58% year-over-year. These metrics reflect the company's stable position within the pharmaceuticals and biotechnology sector.